Auf dieser Seite
01MDT Preis
02Momentaufnahme
03Chart
04Aktiensplits
05Über uns
06Performance
07Bewertung & Kennzahlen
13Dividenden
14Erträge
15Vollständige Fundamentaldaten
16Erklärungen
17Institutionelle Eigentümer (13F)
18Aktivisten & 5%+-Eigentümer
19Unternehmensinsider
20ETF-Besitz
21Konsens
22Peers
23Nachrichten
26Meine Kennzahlen
MDT Medtronic plc. Ordinary Shares
NYSE · Health Care · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Sep 3, 2026
$86,38
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$73,3152-Wochen-Tief
$106,3352-Wochen-Hoch
Marktkapitalisierung (MRQ)
$110.57B
P/E (TTM)
21.3
EPS (TTM)
$4.06
Umsatz (TTM)
$37.54B
Ihre Abzeichen
52W-Spanne
$73–$106
Analystenbewertung
BUY
Kursziel
$105
P/E
21.3
ROE
10.7%
Nettogewinnmarge
13.9%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
MDT Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$86.38
Marktkapitalisierung (MRQ)
$110.57B
P/E (TTM)
21.3
EPS (TTM)
$4.06
Umsatz (TTM)
$37.54B
Dividendenrendite
3.3%
ROE (TTM)
10.7%
52W-Spanne
$73–$106
MDT Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 27. September 1999 | 2-for-1 | Vorwärts |
| 15. September 1997 | 2-for-1 | Vorwärts |
| 29. September 1995 | 2-for-1 | Vorwärts |
| 30. September 1994 | 2-for-1 | Vorwärts |
| 30. August 1991 | 2-for-1 | Vorwärts |
| 31. August 1989 | 2-for-1 | Vorwärts |
| 1. August 1980 | 2-for-1 | Vorwärts |
Über Medtronic plc. Ordinary Shares Unternehmensübersicht von Wikipedia
Medtronic plc mit Hauptsitz in Dublin ist ein börsennotiertes Unternehmen auf dem Gebiet der Medizintechnik. Das Unternehmen ist in den Aktienindizes S&P 100 und S&P 500 sowie dem Global Challenges Index vertreten.
Bekannt ist die Firma für ihre Herzschrittmacher, implantierbare Kardioverter-Defibrillatoren, Herzklappen, Insulinpumpen, Aortenstentgrafts, Koronarstents und Neurostimulatoren. Von Medtronic werden mehr als die Hälfte aller weltweit implantierten Herzschrittmacher hergestellt.
Geschichte
Das Unternehmen wurde 1949 von Earl Bakken und Palmer Hermundslie gegründet. Momentan sind 91.000 Mitarbeiter bei Medtronic beschäftigt, die einen Umsatz von rund 29,7 Mrd. US-Dollar generieren.
Im Juni 2014 wurden Pläne bekannt, den irischen Konkurrenten Covidien zu kaufen. Die Übernahme wurde am 27. Januar 2015 abgeschlossen und der Sitz von Medtronic von Fridley, Minnesota nach Dublin verlegt.
Im August 2016 gab Medtronic die Übernahme von HeartWare International bekannt.
Deutschland
Die Medtronic GmbH in Deutschland hat seit 1970 ihren Sitz in Meerbusch. Ende 2008 wurde dort der neue Deutschlandsitz bezogen. Dort arbeiten etwa 240 der rund 800 deutschen Mitarbeiter.
Europa
Die Medtronic Österreich GmbH wurde am 12. April 1973 gegründet und hat ihren Sitz in Wien. Medtronics Hauptsitz für EMEA befindet sich in Tolochenaz (VD) in der Schweiz. In Europa sind über 6.000 Mitarbeiter tätig.
Image-, Produkt- und Sicherheitsprobleme
Implant files
Im November 2018 berichtete die Süddeutsche Zeitung im Zuge der Implant Files genannten internationalen Recherchen zu mangelhaften Implantaten: „Seit Jahren steht Medtronic im Ruf, in Interessenkonflikte, Steuertricks und Korruption verstrickt zu sein.“
ICD-Elektroden
Ende 2007 wurde bekannt, dass die Elektroden der Serie Sprint Fidelis unter Umständen brechen können und mit fünf Todesfällen in den USA in Zusammenhang gebracht werden, Medtronic zahlte im Jahr 2010 an 3.700 Kläger 268 Mio. US-Dollar.
IT-Sicherheitslücken
Anfang des Jahres 2017 informierten die Hacker Billy Rios und Jonathan Butts das Unternehmen über eine Schwachstelle in seinen Insulinpumpen. Rios und Butts programmierten u. a. eine Android-App, mit der sich indirekt die Insulindosierung mehrerer Pumpen aus verschiedenen Serien drahtlos manipulieren ließ. Erst Mitte 2019 reagierte Medtronic auf diese Informationen mittels eines Rückrufs. Außerdem wurden im August 2018 schwere Sicherheitslücken in der Software der Herzschrittmacher Adapta bekannt. Diese lassen sich mit geringem Aufwand dazu bewegen, manipulierte Firmware auszuführen oder den Betrieb ganz einzustellen. Auch hierauf wurde Medtronic von Rios und Butts bereits 18 Monate zuvor hingewiesen, zeigte sich aber unwillig, Abhilfe zu schaffen, weshalb Rios den Bug veröffentlichte. Im Oktober 2018 erhielt Medtronic dafür den österreichischen Negativpreis Big Brother Award in der Kategorie Business und Finanzen. Die US-amerikanische Cybersecurity and Infrastructure Security Agency (CISA) warnte in einem Beitrag Anfang des Jahres 2019 über zwei ähnliche Sicherheitslücken in vielen Defibrillator-Implantaten des Herstellers. Stand Januar 2020 sind diese Lücken für einige Modelle mittlerweile geschlossen, aber für andere weiterhin offen.
Vorwürfe zu Lücken im Datenschutz
Medtronic sieht sich einer Sammelklage gegenüber, die das Unternehmen und seine Tochtergesellschaft MiniMed beschuldigt, sensible Patientendaten ohne Zustimmung weitergegeben zu haben. Die Klage wurde im Namen eines Nutzers der InPen Diabetes Management App eingereicht, der im April 2023 erfuhr, dass seine persönlichen und geschützten Gesundheitsinformationen an Drittanbieter wie Google weitergeleitet wurden. Zu den weitergegebenen Daten gehören Namen, Telefonnummern, E-Mail-Adressen, IP-Adressen, Gerätekennungen und andere sensible medizinische Informationen.
Die Klage argumentiert, dass Medtronic und MiniMed bewusst entschieden haben, Tracking- und Authentifizierungstechnologien wie Google Analytics, Crashlytics und Firebase Authentication zu verwenden, um diese Daten zu sammeln und zu teilen. Diese Praktiken stehen im Widerspruch zu den Datenschutzrichtlinien und könnten gegen den Health Insurance Portability and Accountability Act (HIPAA) verstoßen, der den Schutz solcher Informationen sicherstellen soll.
Medtronic wies die Vorwürfe zurück und betonte, dass der Schutz von Patientendaten höchste Priorität habe und dass das Unternehmen robuste Prozesse und Technologien zum Schutz dieser Informationen einsetze.
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealth Care
BrancheHealth Care
Mitarbeiter95.000
LandIE
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$36.36B2017-04-28 → 2026-04-24
EPS$3.732017-04-28 → 2026-04-24
Freier Cashflow$5.43B2017-04-28 → 2026-04-24
Nettogewinnmarge13.9%2017-04-28 → 2026-04-24
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | MDT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | 21.35-Jahres-Durchschnitt ≈27.0 | ≈27.0 | · | · | |
| P/S (TTM) | 2.95-Jahres-Durchschnitt ≈3.5 | ≈3.5 | · | · | |
| K/B (MRQ) | 2.25-Jahres-Durchschnitt ≈2.3 | ≈2.3 | · | · | |
| Kurs / FCF (TTM) | 18.05-Jahres-Durchschnitt ≈22.0 | ≈22.0 | · | · | |
| Kurs / Cashflow (TTM) | 13.85-Jahres-Durchschnitt ≈16.8 | ≈16.8 | · | · | |
| Kurs / Materieller Buchwert (MRQ) | 2.8 | · | · | · | |
| PEG Ratio (PEG-Ratio) | ≈3.0 | · | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | MDT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | 18.1%5-Jahres-Durchschnitt ≈17.4% | ≈17.4% | · | · | |
| EBITDA-Marge (TTM) | 25.9%5-Jahres-Durchschnitt ≈25.8% | ≈25.8% | · | · | |
| Vorgewinnmarge (TTM) | 17.6%5-Jahres-Durchschnitt ≈16.6% | ≈16.6% | · | · | |
| Nettogewinnmarge (TTM) | 13.9%5-Jahres-Durchschnitt ≈13.3% | ≈13.3% | · | · | |
| ROA (TTM) | 5.7%5-Jahres-Durchschnitt ≈4.8% | ≈4.8% | · | · | |
| ROE (TTM) | 10.7%5-Jahres-Durchschnitt ≈8.7% | ≈8.7% | · | · | |
| ROIC | 10.3%5-Jahres-Durchschnitt ≈9.2% | ≈9.2% | · | · |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | MDT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 2.15-Jahres-Durchschnitt ≈2.1 | ≈2.1 | · | · | |
| Quick Ratio (MRQ) | 1.35-Jahres-Durchschnitt ≈1.3 | ≈1.3 | · | · |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | MDT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 8.4%5-Jahres-Durchschnitt ≈3.9% | ≈3.9% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 5.2%5-Jahres-Durchschnitt ≈3.2% | ≈3.2% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 3.8% | · | · | · | |
| EPS YoY (EPS VjV) | 3.3%5-Jahres-Durchschnitt ≈9.6% | ≈9.6% | · | · | |
| Net Income YoY (Nettogewinn YoY) | 3.0%5-Jahres-Durchschnitt ≈8.4% | ≈8.4% | · | · | |
| EPS CAGR 3Y (EPS CAGR 3J) | 9.8%5-Jahres-Durchschnitt ≈3.3% | ≈3.3% | · | · | |
| EPS CAGR 5Y (EPS CAGR 5J) | 7.0% | · | · | · | |
| Net Income CAGR 3Y (Nettoergebnis CAGR 3J) | 8.5%5-Jahres-Durchschnitt ≈2.2% | ≈2.2% | · | · | |
| Net Income CAGR 5Y (Nettoergebnis CAGR 5J) | 5.9% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | MDT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.45-Jahres-Durchschnitt ≈0.4 | ≈0.4 | · | · | |
| Inventory Turnover (Lagerumschlag) | 2.25-Jahres-Durchschnitt ≈2.2 | ≈2.2 | · | · | |
| Receivables Turnover (Forderungsumschlag) | 5.55-Jahres-Durchschnitt ≈5.5 | ≈5.5 | · | · | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$382.8K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Dividenden Rendite, Ausschüttungsquote, Dividendenhistorie, 5-Jahres-CAGR
Dividendenrendite3.3%
Ausschüttungsquote75.8%
Annualisierte Auszahlung≈$2.88
5J Div CAGR≈4.1%
Wachstumsphase≈42
| Ex-Datum | Betrag | Währung | Rendite |
|---|---|---|---|
| Sep 25, 2026 | $0,72 | USD | ≈3.2% |
| Jun 26, 2026 | $0,72 | USD | ≈3.5% |
| Mär 27, 2026 | $0,71 | USD | ≈3.3% |
| Dez 26, 2025 | $0,71 | USD | ≈2.9% |
| Sep 26, 2025 | $0,71 | USD | ≈3.0% |
| Jun 27, 2025 | $0,71 | USD | ≈3.3% |
| Mär 28, 2025 | $0,70 | USD | ≈3.2% |
| Dez 27, 2024 | $0,70 | USD | ≈3.5% |
| Sep 27, 2024 | $0,70 | USD | ≈3.1% |
| Jun 28, 2024 | $0,70 | USD | ≈3.5% |
| Mär 21, 2024 | $0,69 | USD | ≈3.3% |
| Dez 19, 2023 | $0,69 | USD | ≈3.4% |
| Sep 21, 2023 | $0,69 | USD | ≈3.4% |
| Jun 22, 2023 | $0,69 | USD | ≈3.1% |
| Mär 23, 2023 | $0,68 | USD | ≈3.5% |
| Dez 20, 2022 | $0,68 | USD | ≈3.5% |
| Sep 22, 2022 | $0,68 | USD | ≈3.1% |
| Jun 23, 2022 | $0,68 | USD | ≈2.9% |
| Mär 24, 2022 | $0,63 | USD | ≈2.4% |
| Dez 21, 2021 | $0,63 | USD | ≈2.4% |
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Beat Rate
75.0%
Durchschn. Überraschung
1.6%
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 31. März 2027 | Sep 1, 2026 | $1.45 | $1.40 | 3.4% |
| 31. Dezember 2026 | Jun 3, 2026 | $1.55 | $1.56 | -0.43% |
| 30. September 2026 | $1.45 | $1.40 | 3.4% | |
| 30. Juni 2026 | $1.55 | $1.56 | -0.43% | |
| 31. März 2026 | $1.36 | $1.35 | 0.89% | |
| 31. Dezember 2025 | $1.36 | $1.33 | 2.4% | |
| 30. September 2025 | $1.26 | $1.24 | 1.5% | |
| 30. Juni 2025 | $1.62 | $1.59 | 1.6% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.36B | $33.54B | $32.36B | $31.23B | $31.69B | $30.12B | $28.91B | $30.56B | $29.95B | $29.71B | $28.83B | $20.26B | |
| Cost of Revenue | $12.72B | $11.63B | $11.22B | $10.72B | $10.14B | $10.48B | $9.42B | $9.15B | $9.07B | $9.29B | $9.14B | $6.31B | |
| Gross Profit | · | · | · | · | · | · | · | · | $20.90B | $20.42B | $19.69B | $13.95B | |
| SG&A Expense | $11.78B | $10.85B | $10.74B | $10.41B | $10.29B | $10.15B | $10.11B | $10.42B | $10.24B | $10.02B | $9.47B | $6.90B | |
| Operating Income | $6.47B | $5.96B | $5.14B | $5.49B | $5.75B | $4.48B | $4.79B | $6.27B | $6.64B | $5.38B | $5.36B | $3.77B | |
| Interest Expense | · | · | $719M | $636M | $553M | $925M | $1.09B | $1.44B | $1.15B | $1.09B | $1.39B | $666M | |
| Other Non-op | $384M | $402M | $412M | $515M | $318M | $336M | $356M | $373M | $181M | $313M | $-107M | $-118M | |
| Pretax Income | $6.14B | $5.63B | $4.84B | $5.36B | $5.52B | $3.90B | $4.05B | $5.20B | $5.67B | $4.60B | $4.34B | $3.49B | |
| Income Tax | $1.30B | $936M | $1.13B | $1.58B | $456M | $265M | $-751M | $547M | $2.58B | $578M | $798M | $811M | |
| Net Income | $4.80B | $4.66B | $3.68B | $3.76B | $5.04B | $3.61B | $4.79B | $4.63B | $3.10B | $4.03B | $3.54B | $2.67B | |
| EPS (Basic) | $3.75 | $3.63 | $2.77 | $2.83 | $3.75 | $2.68 | $3.57 | $3.44 | $2.29 | $2.92 | $2.51 | $2.44 | |
| EPS (Diluted) | $3.73 | $3.61 | $2.76 | $2.82 | $3.73 | $2.66 | $3.54 | $3.41 | $2.27 | $2.89 | $2.48 | $2.41 | |
| Shares (Basic) | 1,281,800,000 | 1,285,600,000 | 1,327,700,000 | 1,329,800,000 | 1,342,400,000 | 1,344,900,000 | 1,340,700,000 | 1,346,400,000 | 1,356,700,000 | 1,378,900,000 | 1,409,600,000 | 1,095,500,000 | |
| Shares (Diluted) | 1,288,100,000 | 1,289,900,000 | 1,330,200,000 | 1,332,800,000 | 1,351,400,000 | 1,354,000,000 | 1,351,100,000 | 1,357,500,000 | 1,368,200,000 | 1,391,400,000 | 1,425,900,000 | 1,109,000,000 | |
| EBITDA | $9.43B | $8.82B | $7.79B | $8.18B | $8.46B | $7.19B | $7.45B | $8.93B | $9.29B | $8.25B | $8.11B | $5.07B |
Bilanz
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.95B | $2.22B | $1.28B | $1.54B | $3.71B | $3.59B | $4.14B | $4.39B | $3.67B | $4.97B | $2.88B | $4.84B | |
| Short-term Investments | $7.27B | $6.75B | $6.72B | $6.42B | $6.86B | $7.22B | $6.81B | $5.46B | $7.56B | $8.74B | $9.76B | $14.64B | |
| Receivables | $6.64B | $6.51B | $6.13B | $6.00B | $5.55B | $5.46B | $4.64B | $6.22B | $5.99B | $5.59B | $5.56B | $5.11B | |
| Inventory | $5.95B | $5.48B | $5.22B | $5.29B | $4.62B | $4.31B | $4.23B | $3.75B | $3.58B | $3.34B | $3.47B | $3.46B | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | $1.86B | $1.93B | $1.45B | |
| Other Current Assets | $2.97B | $2.86B | $2.58B | $2.42B | $2.32B | $1.96B | $2.21B | $2.14B | $2.19B | $1.86B | $1.93B | · | |
| Current Assets | $24.79B | $23.81B | $21.93B | $21.68B | $23.06B | $22.55B | $22.03B | $21.97B | $22.98B | $24.87B | $23.60B | $30.84B | |
| PP&E (Net) | $7.42B | $6.84B | $6.13B | $5.57B | $5.41B | $5.22B | $4.83B | $4.67B | $4.60B | $4.36B | $4.84B | $4.70B | |
| PP&E (Gross) | · | · | · | · | $13.37B | $12.70B | $11.64B | $10.92B | $10.26B | $9.69B | $9.71B | $8.86B | |
| Accum. Depreciation | · | · | · | · | $7.95B | $7.48B | $6.82B | $6.25B | $5.66B | $5.33B | $4.87B | $4.16B | |
| Goodwill | $42.59B | $41.74B | $40.99B | $41.42B | $40.50B | $41.96B | $39.84B | $39.96B | $39.54B | $38.52B | $41.50B | $40.53B | |
| Intangibles | $10.15B | $11.67B | $13.22B | $14.84B | $15.60B | $17.74B | $19.06B | $20.56B | $21.72B | $23.41B | $26.90B | $28.10B | |
| Other Non-current Assets | $4.15B | $3.58B | $4.05B | $3.96B | $3.01B | $2.44B | $2.09B | $1.01B | $1.08B | $1.23B | $1.42B | $1.74B | |
| Total Assets | $93.03B | $91.68B | $89.98B | $90.95B | $90.98B | $93.08B | $90.69B | $89.69B | $91.39B | $99.86B | $99.64B | $106.69B | |
| Accounts Payable | $2.64B | $2.45B | $2.41B | $2.66B | $2.28B | $2.11B | $2.00B | $1.95B | $1.63B | $1.55B | $1.71B | $1.61B | |
| Short-term Debt | · | $0 | $1.07B | $0 | · | · | · | · | · | · | · | · | |
| Current Liabilities | $11.66B | $12.88B | $10.79B | $9.05B | $12.39B | $8.51B | $10.37B | $8.47B | $10.08B | $14.26B | $7.17B | $9.17B | |
| Capital Leases | $989M | $918M | $840M | $869M | $703M | $829M | $774M | $10M | · | · | · | · | |
| Deferred Tax | $362M | $403M | $515M | $708M | $884M | $1.03B | $1.17B | $1.28B | $1.42B | $2.98B | $3.73B | $4.70B | |
| Other Non-current Liabilities | $2.06B | $1.77B | $1.36B | $1.73B | $1.41B | $1.76B | $1.66B | $757M | $889M | $1.51B | $1.92B | $1.82B | |
| Total Liabilities | $42.96B | $43.42B | $39.56B | $39.28B | $38.26B | $41.48B | $39.82B | $39.48B | $40.57B | $49.53B | $47.58B | $53.45B | |
| Long-term Debt | · | · | · | · | · | · | $24.92B | $25.39B | $25.75B | $33.37B | $30.94B | $35.59B | |
| Total Debt | · | $0 | $1.07B | · | · | · | $24.92B | $25.39B | $25.75B | $33.37B | $30.94B | $35.59B | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Paid-in Capital | $20.93B | $20.83B | $23.13B | $24.59B | $24.57B | $26.32B | $26.16B | $26.53B | $28.13B | $29.55B | $32.23B | · | |
| Retained Earnings | $32.64B | $31.48B | $30.40B | $30.39B | $30.25B | $28.59B | $28.13B | $26.27B | $24.38B | $23.27B | $21.70B | $54.41B | |
| AOCI | $-4.10B | $-4.28B | $-3.32B | $-3.50B | $-2.27B | $-3.48B | $-3.56B | $-2.71B | $-1.79B | $-2.61B | $-1.87B | $-1.18B | |
| Stockholders' Equity | $49.46B | $48.02B | $50.21B | $51.48B | $52.55B | $51.43B | $50.74B | $50.09B | $50.72B | $50.21B | $52.06B | $53.23B | |
| Liabilities + Equity | $93.03B | $91.68B | $89.98B | $90.95B | $90.98B | $93.08B | $90.69B | $89.69B | $91.39B | $99.86B | $99.64B | $106.69B | |
| Shares Outstanding | 1,280,177,293 | 1,282,000,000 | 1,311,000,000 | 1,331,000,000 | 1,331,000,000 | 1,345,000,000 | 1,341,000,000 | 1,341,000,000 | 1,354,000,000 | 1,369,000,000 | 1,399,000,000 | 1,422,000,000 |
Cashflow
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2.96B | $2.86B | $2.65B | $2.70B | $2.71B | $2.70B | $2.66B | $2.66B | $2.64B | $2.92B | $2.82B | $1.31B | |
| Stock-based Comp | $457M | $429M | $393M | $355M | $359M | $344M | $297M | $290M | $344M | $348M | $375M | $439M | |
| Deferred Tax | $31M | $-339M | $-528M | $-253M | $-611M | $-461M | $-1.28B | $-438M | $-1.11B | $-876M | $-477M | $-819M | |
| Amort. of Intangibles | $1.77B | $1.81B | $1.69B | $1.70B | $1.73B | $1.78B | $1.76B | $1.76B | $1.82B | $1.98B | $1.90B | $733M | |
| Restructuring | · | · | $389M | $647M | $335M | $539M | $462M | · | · | · | · | · | |
| Other Non-cash | $-917M | $-569M | $599M | $-518M | $-148M | $49M | $762M | $-135M | $-293M | $463M | $-1.04B | $1.30B | |
| Operating Cash Flow | $7.33B | $7.04B | $6.79B | $6.04B | $7.35B | $6.24B | $7.23B | $7.01B | $4.68B | $6.88B | $5.22B | $4.90B | |
| CapEx | $1.90B | $1.86B | $1.59B | $1.46B | $1.37B | $1.35B | $1.21B | $1.13B | $1.07B | $1.25B | $1.05B | $571M | |
| Investing Cash Flow | $-2.93B | $-1.94B | $-2.37B | $-3.49B | $-1.66B | $-2.87B | $-3.20B | $-774M | $5.86B | $-1.57B | $2.25B | $-17.06B | |
| Debt Issued | $1.75B | $3.21B | $0 | $5.41B | $0 | $7.17B | $5.57B | $7.79B | $21M | $2.14B | $0 | $19.94B | |
| Net Debt Issued | $-1.18B | $3.21B | $0 | $-603M | $-1M | $-195M | $-542M | $-154M | $-7.35B | $1.28B | $-5.13B | $18.67B | |
| Stock Issued | $516M | $508M | $284M | · | · | · | · | · | · | · | · | · | |
| Stock Repurchased | $1.03B | $3.23B | $2.14B | $645M | $2.54B | $652M | $1.33B | $2.88B | $2.17B | $3.54B | $2.83B | $1.92B | |
| Net Stock Activity | $-519M | $-3.23B | $-2.14B | $-645M | $-2.54B | $-652M | $-1.33B | $-2.88B | $-2.17B | $-3.54B | $-2.83B | $-1.92B | |
| Dividends Paid | $3.64B | $3.59B | $3.67B | $3.62B | $3.38B | $3.12B | $2.89B | $2.69B | $2.49B | $2.38B | $2.14B | $1.34B | |
| Financing Cash Flow | $-4.75B | $-4.36B | $-4.45B | $-4.96B | $-5.34B | $-4.14B | $-4.20B | $-5.43B | $-11.95B | $-3.28B | $-9.54B | $15.95B | |
| Net Change in Cash | $-269M | $934M | $-259M | $-2.17B | $121M | $-547M | $-253M | $724M | $-1.30B | $2.09B | $-1.97B | $3.44B | |
| Taxes Paid | $1.94B | $1.82B | $1.62B | $1.55B | $996M | $1.25B | $878M | $1.56B | $2.54B | $1.03B | $1.38B | $632M | |
| Free Cash Flow | $5.43B | $5.18B | $5.20B | $4.58B | $5.98B | $4.88B | $6.02B | $5.87B | $3.62B | $5.63B | $4.17B | $4.33B | |
| Levered FCF | · | · | $4.65B | $4.13B | $5.47B | $4.02B | $4.73B | $4.58B | $2.99B | $4.67B | $3.04B | $3.82B |
Rentabilität
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | · | · | · | 69.8% | 68.7% | 68.3% | 68.9% | |
| Operating Margin | 17.8% | 17.8% | 15.9% | 17.6% | 18.1% | 14.9% | 16.6% | 20.5% | 22.2% | 17.9% | 18.4% | 18.6% | |
| Net Margin | 13.2% | 13.9% | 11.4% | 12.0% | 15.9% | 12.0% | 16.6% | 15.2% | 10.4% | 13.6% | 12.3% | 13.2% | |
| Pretax Margin | 16.9% | 16.8% | 14.9% | 17.2% | 17.4% | 12.9% | 14.0% | 17.0% | 18.9% | 15.5% | 15.0% | 17.2% | |
| EBITDA Margin | 25.9% | 26.3% | 24.1% | 26.2% | 26.7% | 23.9% | 25.8% | 29.2% | 31.0% | 27.8% | 28.1% | 25.0% | |
| ROA | 5.2% | 5.1% | 4.1% | 4.1% | 5.5% | 3.9% | 5.3% | 5.1% | 3.2% | 4.0% | 3.4% | 3.7% | |
| ROE | 9.8% | 9.5% | 7.2% | 7.2% | 9.7% | 7.1% | 9.5% | 9.2% | 6.2% | 7.9% | 6.7% | 7.4% | |
| ROIC | 10.3% | 10.3% | 7.7% | 7.5% | 10.0% | 8.1% | 7.5% | 7.4% | 4.7% | 5.6% | 5.2% | 3.2% |
Liquidität & Solvenz
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 1.8 | 2.0 | 2.4 | 1.9 | 2.6 | 2.1 | 2.6 | 2.3 | 1.7 | 3.3 | 3.4 | |
| Quick Ratio | 1.4 | 1.2 | 1.3 | 1.5 | 1.3 | 1.9 | 1.5 | 1.9 | 1.7 | 1.4 | 2.5 | 2.7 | |
| Debt / Equity | · | 0.0 | 0.0 | · | · | · | 0.5 | 0.5 | 0.5 | 0.7 | 0.6 | 0.7 | |
| LT Debt / Equity | · | · | · | · | · | · | 0.4 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | |
| Interest Coverage | · | · | 7.2 | 8.6 | 10.4 | 4.8 | 4.4 | 4.3 | 5.8 | 4.9 | 3.8 | 5.7 |
Effizienz
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| Inventory Turnover | 2.2 | 2.2 | 2.1 | 2.2 | 2.3 | 2.5 | 2.4 | 2.5 | 2.6 | 2.7 | 2.6 | 2.4 | |
| Receivables Turnover | 5.5 | 5.3 | 5.3 | 5.4 | 5.8 | 6.0 | 5.3 | 5.0 | 5.2 | 5.3 | 5.4 | 4.5 |
Pro Aktie
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $38.64 | $37.46 | $38.29 | $38.69 | $39.49 | $38.23 | $37.83 | $37.36 | $37.45 | $36.73 | $37.21 | $37.44 | |
| Revenue / Share | $28.23 | $26.00 | $24.33 | $23.43 | $23.45 | $22.24 | $21.40 | $22.51 | $21.89 | $21.35 | $20.22 | $18.27 | |
| Cash Flow / Share | $5.69 | $5.46 | $5.10 | $4.53 | $5.44 | $4.61 | $5.35 | $5.16 | $3.42 | $4.94 | $3.66 | $4.42 | |
| Cash / Share | $1.52 | $1.73 | $0.98 | $1.16 | $2.79 | $2.67 | $3.09 | $3.28 | $2.71 | $3.63 | $2.06 | $3.41 | |
| Dividend / Share | $2.84 | $2.80 | $2.76 | $2.72 | $2.52 | $2.32 | $2.16 | $2.00 | $1.84 | $1.72 | $1.52 | $1.22 | |
| EPS (TTM) | $3.73 | $3.61 | $2.76 | $2.82 | $3.73 | $2.66 | $3.54 | $3.41 | $2.27 | $2.89 | $2.48 | $2.41 |
Wachstumsraten
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 8.4% | 3.6% | 3.6% | -1.5% | 5.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.2% | 1.9% | 2.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.8% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 3.3% | 30.8% | -2.1% | -24.4% | 40.2% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 9.8% | -1.1% | 1.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 7.0% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 3.0% | 26.8% | -2.2% | -25.4% | 39.7% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 8.5% | -2.6% | 0.64% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 5.9% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 3.1% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $36.36B | $33.54B | $32.36B | $31.23B | $31.69B | $30.12B | $28.91B | $30.56B | $29.95B | $29.71B | $28.83B | $20.26B | |
| Net Income TTM | $4.80B | $4.66B | $3.68B | $3.76B | $5.04B | $3.61B | $4.79B | $4.63B | $3.10B | $4.03B | $3.54B | $2.67B | |
| Market Cap | $106.66B | $107.89B | $104.57B | $121.04B | $138.88B | $176.14B | $133.17B | $117.11B | $110.08B | $113.79B | $110.73B | $110.33B | |
| Enterprise Value | · | $98.92B | $97.63B | · | · | · | $147.14B | $132.65B | $124.61B | $133.45B | $129.04B | $126.44B | |
| P/E | 22.3 | 23.3 | 28.9 | 32.3 | 28.0 | 49.2 | 28.1 | 25.6 | 35.8 | 28.8 | 31.9 | 32.2 | |
| P/S | 2.9 | 3.2 | 3.2 | 3.9 | 4.4 | 5.8 | 4.6 | 3.8 | 3.7 | 3.8 | 3.8 | 5.4 | |
| P/B | 2.2 | 2.2 | 2.1 | 2.4 | 2.6 | 3.4 | 2.6 | 2.3 | 2.2 | 2.3 | 2.1 | 2.1 | |
| P / Cash Flow | 14.6 | 15.3 | 15.4 | 20.0 | 18.9 | 28.2 | 18.4 | 16.7 | 23.5 | 16.5 | 21.2 | 22.5 | |
| P / FCF | 19.7 | 20.8 | 20.1 | 26.4 | 23.2 | 36.1 | 22.1 | 19.9 | 30.4 | 20.2 | 26.5 | 25.5 | |
| EV / EBITDA | · | 11.2 | 12.5 | · | · | · | 19.7 | 14.9 | 13.4 | 16.2 | 15.9 | 24.9 | |
| EV / FCF | · | 19.1 | 18.8 | · | · | · | 24.4 | 22.6 | 34.5 | 23.7 | 30.9 | 29.2 | |
| EV / Revenue | · | 2.9 | 3.0 | · | · | · | 5.1 | 4.3 | 4.2 | 4.5 | 4.5 | 6.2 | |
| Dividend Yield | 3.4% | 3.3% | 3.5% | 3.0% | 2.4% | 1.8% | 2.2% | 2.3% | 2.3% | 2.1% | 1.9% | 1.2% | |
| Earnings Yield | 4.5% | 4.3% | 3.5% | 3.1% | 3.6% | 2.0% | 3.6% | 3.9% | 2.8% | 3.5% | 3.1% | 3.1% | |
| Payout Ratio | 75.8% | 77.0% | 99.7% | 96.2% | 67.1% | 86.5% | 60.4% | 58.1% | 80.3% | 59.0% | 60.5% | 50.0% | |
| Annual Payout | $3.64B | $3.59B | $3.67B | $3.62B | $3.38B | $3.12B | $2.89B | $2.69B | $2.49B | $2.38B | $2.14B | $1.34B |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.76B | $9.81B | $9.02B | $8.96B | $8.58B | $8.93B | $8.29B | $8.40B | $7.92B | $8.59B | $8.09B | $7.98B | $7.70B | $8.54B | $7.73B | $7.58B | |
| Cost of Revenue | $3.42B | $3.40B | $3.26B | $3.06B | $3.00B | $3.15B | $2.78B | $2.95B | $2.76B | $3.04B | $2.78B | $2.76B | $2.63B | $2.98B | $2.69B | $2.54B | |
| SG&A Expense | $3.20B | $3.06B | $2.96B | $2.96B | $2.81B | $2.72B | $2.72B | $2.76B | $2.65B | $2.76B | $2.67B | $2.69B | $2.61B | $2.62B | $2.62B | $2.62B | |
| Operating Income | $1.76B | $1.87B | $1.46B | $1.69B | $1.45B | $1.44B | $1.65B | $1.59B | $1.28B | $1.05B | $1.48B | $1.34B | $1.27B | $1.56B | $1.39B | $1.40B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | $188M | $180M | $148M | · | $167M | $118M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | $170M | $148M | $111M | · | $118M | $73M | |
| Other Non-op | $190M | $138M | $121M | $92M | $33M | $0 | $72M | $173M | $157M | $5M | $177M | $154M | $76M | $174M | $149M | $109M | |
| Pretax Income | $1.77B | $1.83B | $1.40B | $1.60B | $1.30B | $1.26B | $1.54B | $1.56B | $1.27B | $856M | $1.47B | $1.31B | $1.20B | $1.55B | $1.38B | $1.40B | |
| Income Tax | $289M | $575M | $254M | $215M | $255M | $198M | $237M | $281M | $220M | $196M | $135M | $402M | $400M | $363M | $146M | $959M | |
| Net Income | $1.47B | $1.24B | $1.14B | $1.37B | $1.04B | $1.06B | $1.29B | $1.27B | $1.04B | $654M | $1.32B | $909M | $791M | $1.18B | $1.22B | $427M | |
| EPS (Basic) | $1.15 | $0.98 | $0.89 | $1.07 | $0.81 | $0.82 | $1.01 | $0.99 | $0.81 | $0.51 | $0.99 | $0.68 | $0.59 | $0.89 | $0.92 | $0.32 | |
| EPS (Diluted) | $1.14 | $0.96 | $0.89 | $1.07 | $0.81 | $0.81 | $1.01 | $0.99 | $0.80 | $0.50 | $0.99 | $0.68 | $0.59 | $0.88 | $0.92 | $0.32 | |
| Shares (Basic) | 1,279,800,000 | · | 1,282,600,000 | 1,282,000,000 | 1,281,600,000 | · | 1,282,400,000 | 1,282,400,000 | 1,293,300,000 | · | 1,329,700,000 | 1,330,200,000 | 1,330,500,000 | · | 1,330,200,000 | 1,329,400,000 | |
| Shares (Diluted) | 1,285,100,000 | · | 1,289,500,000 | 1,288,000,000 | 1,287,100,000 | · | 1,286,200,000 | 1,286,900,000 | 1,296,500,000 | · | 1,331,700,000 | 1,331,900,000 | 1,333,800,000 | · | 1,332,000,000 | 1,332,000,000 | |
| EBITDA | $2.49B | · | $1.46B | $1.69B | $2.19B | · | $1.65B | $1.59B | $1.94B | · | $1.48B | $1.34B | $1.94B | · | $1.39B | $1.40B |
Bilanz
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.69B | $1.95B | $1.15B | $1.28B | $1.27B | $2.22B | $1.24B | $1.39B | $1.31B | $1.28B | $1.62B | $1.31B | $1.34B | · | $4.52B | $4.83B | |
| Short-term Investments | $7.13B | $7.27B | $7.24B | $7.04B | $6.85B | $6.75B | $6.68B | $6.59B | $6.53B | $6.72B | $6.70B | $6.42B | $6.54B | · | $6.62B | $6.60B | |
| Receivables | $6.36B | $6.64B | $6.36B | $6.39B | $6.26B | $6.51B | $6.12B | $6.26B | $6.01B | $6.13B | $5.97B | $5.93B | $5.81B | · | $5.89B | $5.63B | |
| Inventory | $6.21B | $5.95B | $6.31B | $6.16B | $5.89B | $5.48B | $5.61B | $5.48B | $5.41B | $5.22B | $5.73B | $5.75B | $5.67B | · | $5.38B | $5.05B | |
| Other Current Assets | $3.00B | $2.97B | $3.02B | $3.12B | $2.95B | $2.86B | $2.87B | $2.71B | $2.68B | $2.58B | $2.50B | $2.66B | $2.52B | · | $2.96B | $3.29B | |
| Current Assets | $24.39B | $24.79B | $24.07B | $24.00B | $23.22B | $23.81B | $22.51B | $22.44B | $21.95B | $21.93B | $22.51B | $22.08B | $21.87B | · | $25.36B | $25.40B | |
| PP&E (Net) | $7.47B | $7.42B | $7.18B | $7.16B | $7.01B | $6.84B | $6.59B | $6.44B | $6.28B | $6.13B | $5.84B | $5.74B | $5.67B | · | $5.44B | $5.30B | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $13.93B | $13.50B | |
| Accum. Depreciation | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $8.49B | $8.20B | |
| Goodwill | $43.19B | $42.59B | $41.89B | $41.81B | $42.01B | $41.74B | $40.82B | $41.16B | $41.08B | $40.99B | $41.16B | $40.82B | $41.44B | $41.42B | $41.56B | $40.42B | |
| Intangibles | $10.24B | $10.15B | $10.34B | $10.77B | $11.22B | $11.67B | $12.18B | $12.42B | $12.82B | $13.22B | $13.69B | $14.06B | $14.43B | · | $15.27B | $15.65B | |
| Other Non-current Assets | $4.32B | $4.15B | $4.04B | $3.75B | $3.58B | $3.58B | $4.25B | $4.01B | $4.06B | $4.05B | $4.04B | $3.96B | $3.91B | · | $3.14B | $3.12B | |
| Total Assets | $93.31B | $93.03B | $91.48B | $91.35B | $90.97B | $91.68B | $89.97B | $90.04B | $89.75B | $89.98B | $90.84B | $90.09B | $90.78B | · | $94.13B | $93.24B | |
| Accounts Payable | $2.69B | $2.64B | $2.57B | $2.58B | $2.56B | $2.45B | $2.29B | $2.38B | $2.29B | $2.41B | $1.99B | $2.17B | $2.24B | · | $2.21B | $2.20B | |
| Short-term Debt | · | · | · | · | · | $0 | · | · | · | $1.07B | · | · | · | · | · | · | |
| Current Liabilities | $11.80B | $11.66B | $9.49B | $9.94B | $11.53B | $12.88B | $11.84B | $12.20B | $10.29B | $10.79B | $9.79B | $9.66B | $9.05B | · | $14.42B | $14.46B | |
| Capital Leases | · | $989M | · | · | · | $918M | · | · | · | $840M | · | · | · | · | · | · | |
| Deferred Tax | $349M | $362M | $365M | $386M | $416M | $403M | $452M | $473M | $496M | $515M | $615M | $686M | $687M | · | $747M | $871M | |
| Other Non-current Liabilities | $2.00B | $2.06B | $1.77B | $1.76B | $1.81B | $1.77B | $1.53B | $1.53B | $1.47B | $1.36B | $1.41B | $1.56B | $1.72B | · | $1.73B | $1.44B | |
| Total Liabilities | $42.46B | $42.96B | $42.29B | $42.49B | $42.84B | $43.42B | $40.36B | $41.33B | $41.59B | $39.56B | $38.84B | $38.44B | $39.41B | · | $42.52B | $41.18B | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | |
| Paid-in Capital | $20.80B | $20.93B | $21.01B | $20.86B | $20.89B | $20.83B | $20.91B | $20.82B | $20.81B | $23.13B | $24.59B | $24.58B | $24.59B | · | $24.51B | $24.44B | |
| Retained Earnings | $33.19B | $32.64B | $32.30B | $32.07B | $31.61B | $31.48B | $31.32B | $30.92B | $30.55B | $30.40B | $30.66B | $30.26B | $30.27B | · | $30.12B | $29.80B | |
| AOCI | $-3.76B | $-4.10B | $-4.33B | $-4.28B | $-4.60B | $-4.28B | $-2.84B | $-3.25B | $-3.41B | $-3.32B | $-3.46B | $-3.38B | $-3.67B | · | $-3.19B | $-2.36B | |
| Stockholders' Equity | $50.23B | $49.46B | $48.98B | $48.65B | $47.89B | $48.02B | $49.39B | $48.49B | $47.95B | $50.21B | $51.79B | $51.46B | $51.18B | · | $51.44B | $51.88B | |
| Liabilities + Equity | $93.31B | $93.03B | $91.48B | $91.35B | $90.97B | $91.68B | $89.97B | $90.04B | $89.75B | $89.98B | $90.84B | $90.09B | $90.78B | · | $94.13B | $93.24B | |
| Shares Outstanding | 1,280,046,863 | 1,280,177,293 | 1,283,366,516 | 1,281,984,552 | 1,281,869,213 | 1,281,934,628 | 1,283,266,154 | 1,282,553,150 | 1,282,494,588 | 1,311,000,000 | 1,329,653,024 | 1,330,173,450 | 1,330,498,304 | 1,331,000,000 | 1,330,376,287 | 1,330,148,578 |
Cashflow
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $729M | $716M | $749M | $745M | $748M | $840M | $684M | $675M | $662M | $654M | $649M | $672M | $672M | $679M | $679M | $671M | |
| Stock-based Comp | $125M | $95M | $94M | $182M | $86M | $89M | $98M | $159M | $83M | $90M | $84M | $146M | $73M | $75M | $81M | $137M | |
| Amort. of Intangibles | $412M | $409M | $441M | $463M | $459M | $564M | $416M | $413M | $414M | $420M | $419M | $425M | $429M | $423M | $431M | $421M | |
| Restructuring | · | · | $172M | $13M | $67M | · | $46M | $46M | $62M | $300M | $55M | $91M | $91M | $300M | $104M | $95M | |
| Other Non-cash | $-531M | · | · | · | $-786M | · | · | · | $-801M | · | · | · | $-661M | · | · | · | |
| Operating Cash Flow | $1.79B | $2.57B | $2.74B | $925M | $1.09B | $2.53B | $2.57B | $958M | $986M | $2.78B | $2.47B | $661M | $875M | $2.46B | $1.57B | $922M | |
| CapEx | $503M | $488M | $444M | $468M | $504M | $459M | $476M | $404M | $520M | $426M | $346M | $461M | $354M | $378M | $332M | $323M | |
| Investing Cash Flow | $-1.62B | $-917M | $-816M | $-482M | $-719M | $-490M | $-843M | $-345M | $-259M | $-696M | $-707M | $-424M | $-539M | $-475M | $-287M | $-1.15B | |
| Debt Issued | · | $0 | $0 | $1.75B | $0 | $0 | $0 | $0 | $3.21B | $0 | $0 | $0 | $0 | $1.98B | $0 | · | |
| Net Debt Issued | $0 | · | · | · | $-1.16B | · | · | · | $3.21B | · | · | · | $0 | · | · | · | |
| Stock Issued | $20M | · | · | · | $95M | · | · | · | · | · | · | · | · | · | · | · | |
| Stock Repurchased | $267M | $435M | $105M | $372M | $123M | $274M | $181M | $288M | $2.49B | $1.63B | $132M | $226M | $152M | $97M | $71M | $141M | |
| Net Stock Activity | $-247M | · | · | · | $-123M | · | · | · | $-2.49B | · | · | · | $-152M | · | · | · | |
| Dividends Paid | $921M | $908M | $911M | $910M | $910M | $897M | $897M | $897M | $898M | $913M | $917M | $918M | $918M | $905M | $904M | $904M | |
| Financing Cash Flow | $-343M | $-888M | $-2.09B | $-395M | $-1.38B | $-1.34B | $-1.75B | $-534M | $-731M | $-2.36B | $-1.50B | $-90M | $-501M | $-4.89B | $-2.13B | $3.01B | |
| Net Change in Cash | $-258M | $803M | $-136M | $9M | $-945M | $978M | $-154M | $83M | $27M | $-339M | $312M | $-28M | $-204M | $-2.98B | $-306M | $2.69B | |
| Taxes Paid | $199M | $344M | $204M | $992M | $402M | $304M | $180M | $941M | $394M | $219M | $293M | $993M | $117M | $234M | $493M | $561M | |
| Free Cash Flow | $1.29B | · | · | · | $584M | · | · | · | $466M | · | · | · | $521M | · | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | $422M | · | · | · |
Rentabilität
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 18.1% | · | 16.2% | 18.8% | 16.9% | · | 19.9% | 19.0% | 16.2% | · | 18.3% | 16.8% | 16.5% | · | 18.0% | 18.5% | |
| Net Margin | 15.1% | · | 12.7% | 15.3% | 12.1% | · | 15.6% | 15.1% | 13.2% | · | 16.3% | 11.4% | 10.3% | · | 15.8% | 5.6% | |
| Pretax Margin | 18.1% | · | 15.6% | 17.8% | 15.2% | · | 18.6% | 18.6% | 16.0% | · | 18.2% | 16.4% | 15.5% | · | 17.8% | 18.4% | |
| EBITDA Margin | 25.6% | · | 16.2% | 18.8% | 25.6% | · | 19.9% | 19.0% | 24.5% | · | 18.3% | 16.8% | 25.2% | · | 18.0% | 18.5% | |
| ROA | 1.6% | · | 1.3% | 1.5% | 1.1% | · | 1.4% | 1.4% | 1.1% | · | 1.4% | 0.99% | 0.88% | · | 1.3% | 0.46% | |
| ROE | 3.0% | · | 2.3% | 2.8% | 2.2% | · | 2.6% | 2.5% | 2.1% | · | 2.6% | 1.8% | 1.5% | · | 2.4% | 0.82% | |
| ROIC | 2.9% | · | 2.5% | 3.0% | 2.4% | · | 2.8% | 2.7% | 2.2% | · | 2.6% | 1.8% | 1.7% | · | 2.4% | 0.85% |
Liquidität & Solvenz
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | · | 2.5 | 2.4 | 2.0 | · | 1.9 | 1.8 | 2.1 | · | 2.3 | 2.3 | 2.4 | · | 1.8 | 1.8 | |
| Quick Ratio | 1.3 | · | 1.6 | 1.5 | 1.2 | · | 1.2 | 1.2 | 1.3 | · | 1.5 | 1.4 | 1.5 | · | 1.2 | 1.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | 7.9 | 7.4 | 8.6 | · | 8.3 | 11.9 |
Effizienz
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | |
| Inventory Turnover | 0.6 | · | 0.5 | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.5 | · | 0.5 | 0.5 | |
| Receivables Turnover | 1.5 | · | 1.4 | 1.4 | 1.4 | · | 1.4 | 1.4 | 1.3 | · | 1.4 | 1.4 | 1.4 | · | 1.4 | 1.4 |
Pro Aktie
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $39.24 | · | $38.17 | $37.95 | $37.36 | · | $38.49 | $37.81 | $37.39 | · | $38.95 | $38.69 | $38.47 | · | $38.67 | $39.00 | |
| Revenue / Share | $7.59 | · | $6.99 | $6.96 | $6.66 | · | $6.45 | $6.53 | $6.10 | · | $6.07 | $5.99 | $5.77 | · | $5.80 | $5.69 | |
| Cash Flow / Share | $1.40 | · | · | · | $0.85 | · | · | · | $0.76 | · | · | · | $0.66 | · | · | · | |
| Cash / Share | $1.32 | · | $0.89 | $1.00 | $0.99 | · | $0.97 | $1.09 | $1.02 | · | $1.22 | $0.99 | $1.01 | · | $3.40 | $3.63 | |
| Dividend / Share | $0.72 | $0.71 | $0.71 | $0.71 | $0.71 | $0.70 | $0.70 | $0.70 | $0.70 | $0.69 | $0.69 | $0.69 | $0.69 | $0.68 | $0.68 | $0.68 | |
| EPS (TTM) | $4.06 | · | $3.58 | $3.70 | $3.62 | · | $3.30 | $3.28 | $2.97 | · | $3.14 | $3.07 | $2.71 | · | $3.04 | $3.22 |
Bewertung (TTM)
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37.54B | · | $35.48B | $34.76B | $34.20B | · | $33.20B | $33.00B | $32.58B | · | $32.32B | $31.96B | $31.56B | · | $30.77B | $30.81B | |
| Net Income TTM | $5.23B | · | $4.61B | $4.76B | $4.66B | · | $4.26B | $4.29B | $3.93B | · | $4.20B | $4.10B | $3.62B | · | $4.06B | $4.32B | |
| Market Cap | $109.30B | · | $129.47B | $120.08B | $119.14B | · | $115.74B | $116.19B | $100.93B | · | $115.07B | $92.35B | $117.42B | · | $109.86B | $115.48B | |
| P/E | 21.0 | · | 28.2 | 25.3 | 25.7 | · | 27.3 | 27.6 | 26.5 | · | 27.6 | 22.6 | 32.6 | · | 27.2 | 27.0 | |
| P/S | 2.9 | · | 3.6 | 3.5 | 3.5 | · | 3.5 | 3.5 | 3.1 | · | 3.6 | 2.9 | 3.7 | · | 3.6 | 3.7 | |
| P/B | 2.2 | · | 2.6 | 2.5 | 2.5 | · | 2.3 | 2.4 | 2.1 | · | 2.2 | 1.8 | 2.3 | · | 2.1 | 2.2 | |
| P / Cash Flow | 61.0 | · | · | · | 109.5 | · | · | · | 102.4 | · | · | · | 134.2 | · | · | · | |
| Dividend Yield | 3.3% | · | 2.8% | 3.0% | 3.0% | · | 3.1% | 3.1% | 3.6% | · | 3.2% | 4.0% | 3.1% | · | 3.2% | 3.0% | |
| Earnings Yield | 4.8% | · | 3.5% | 4.0% | 3.9% | · | 3.7% | 3.6% | 3.8% | · | 3.6% | 4.4% | 3.1% | · | 3.7% | 3.7% | |
| Payout Ratio | 62.6% | · | · | · | 87.5% | · | · | · | 86.2% | · | · | · | 116.1% | · | · | · | |
| Annual Payout | $3.65B | · | $3.63B | $3.61B | $3.60B | · | $3.60B | $3.62B | $3.65B | · | $3.66B | $3.65B | $3.63B | · | $3.55B | $3.50B |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2026-04-24 | 2025-04-25 | 2024-04-26 | 2023-04-28 | 2022-04-29 |
|---|---|---|---|---|---|
| Umsatz | $36.36B | $33.54B | $32.36B | $31.23B | $31.69B |
| Betriebsgewinnmarge % | 17.8% | 17.8% | 15.9% | 17.6% | 18.1% |
| Nettoergebnis | $4.80B | $4.66B | $3.68B | $3.76B | $5.04B |
| Verwässerte EPS | $3.73 | $3.61 | $2.76 | $2.82 | $3.73 |
| Kennzahl | 2026-04-24 | 2025-04-25 | 2024-04-26 | 2023-04-28 | 2022-04-29 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | · | 0.0 | 0.0 | · | · |
| Liquiditätsgrad | 2.1 | 1.8 | 2.0 | 2.4 | 1.9 |
| Quick Ratio | 1.4 | 1.2 | 1.3 | 1.5 | 1.3 |
| Kennzahl | 2026-04-24 | 2025-04-25 | 2024-04-26 | 2023-04-28 | 2022-04-29 |
|---|---|---|---|---|---|
| Freier Cashflow | $5.43B | $5.18B | $5.20B | $4.58B | $5.98B |
Institutionelle Eigentümer (13F) 2.318 Einreicher · $99.0B gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
2.318
Gehaltener Wert
$99.0B
Neue Positionen
166
Geschlossene Positionen
232
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 166 (-45 vs. Vorquartal) | 232 (+27 vs. Vorquartal) | 841 (-66 vs. Vorquartal) | 924 (+34 vs. Vorquartal) | +28.9M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $12.388.026.608 | 128.961.343 | 12,52% | Aktien |
| BlackRock, Inc. | $8.919.846.142 | 114.020.787 | 9,01% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.556.983.180 | 83.816.735 | 6,63% | Aktien |
| STATE STREET CORP | $5.005.319.950 | 63.399.315 | 5,06% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.664.511.218 | 34.059.967 | 2,69% | Aktien |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $2.606.272.456 | 19.872.600 | 2,63% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $2.352.262.232 | 30.192.015 | 2,38% | Aktien |
| JPMORGAN CHASE & CO | $2.248.597.420 | 27.784.471 | 2,27% | Aktien |
| BANK OF AMERICA CORP /DE/ | $1.668.051.448 | 21.322.401 | 1,69% | Aktien |
| MORGAN STANLEY | $1.521.172.586 | 19.444.871 | 1,54% | Aktien |
| DEUTSCHE BANK AG\ | $1.443.333.878 | 18.449.877 | 1,46% | Aktien |
| Invesco Ltd. | $1.399.155.269 | 17.885.150 | 1,41% | Aktien |
| FRANKLIN RESOURCES INC | $1.373.013.420 | 17.550.983 | 1,39% | Aktien |
| NORGES BANK | $1.294.785.982 | 16.551.016 | 1,31% | Aktien |
| ROYAL BANK OF CANADA | $1.253.751.000 | 16.026.475 | 1,27% | Aktien |
| Bank of New York Mellon Corp | $1.149.531.342 | 14.694.253 | 1,16% | Aktien |
| First Eagle Investment Management, LLC | $1.078.321.025 | 13.783.983 | 1,09% | Aktien |
| Capital Research Global Investors | $1.037.443.303 | 13.261.310 | 1,05% | Aktien |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $1.008.596.703 | 12.892.710 | 1,02% | Aktien |
| NORTHERN TRUST CORP | $909.559.948 | 11.626.741 | 0,92% | Aktien |
| AMERIPRISE FINANCIAL INC | $904.731.875 | 11.565.988 | 0,91% | Aktien |
| WCM INVESTMENT MANAGEMENT, LLC | $876.149.302 | 10.826.014 | 0,89% | Aktien |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $843.429.263 | 9.733.748 | 0,85% | Aktien |
| Legal & General Group Plc | $769.220.262 | 9.832.804 | 0,78% | Aktien |
| GOLDMAN SACHS GROUP INC | $705.025.188 | 9.012.210 | 0,71% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $696.663.105 | 8.905.319 | 0,70% | Aktien |
| Capital World Investors | $655.025.579 | 8.373.074 | 0,66% | Aktien |
| WELLS FARGO & COMPANY/MN | $618.402.719 | 7.904.930 | 0,62% | Aktien |
| Dodge & Cox | $616.131.501 | 7.875.898 | 0,62% | Aktien |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $601.546.143 | 7.689.456 | 0,61% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $579.949.956 | 7.411.228 | 0,59% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $573.774.724 | 6.621.751 | 0,58% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $563.897.017 | 7.208.194 | 0,57% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $556.520.563 | 7.113.902 | 0,56% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $506.498.258 | 6.474.476 | 0,51% | Aktien |
| Aristotle Capital Management, LLC | $492.360.887 | 6.293.698 | 0,50% | Aktien |
| ENVESTNET ASSET MANAGEMENT INC | $482.957.188 | 6.173.570 | 0,49% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $481.385.824 | 6.153.467 | 0,49% | Aktien |
| BARCLAYS PLC | $476.008.037 | 6.084.725 | 0,48% | Aktien |
| STIFEL FINANCIAL CORP | $474.420.367 | 6.064.377 | 0,48% | Aktien |
| Amundi | $455.614.648 | 5.824.040 | 0,46% | Aktien |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | $452.879.494 | 5.789.077 | 0,46% | Aktien |
| UBS Group AG | $434.289.386 | 5.551.443 | 0,44% | Aktien |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $432.933.900 | 5.534.109 | 0,44% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $420.775.311 | 5.378.561 | 0,43% | Aktien |
| CITADEL ADVISORS LLC | $420.398.397 | 5.373.877 | 0,42% | Aktien |
| FEDERATED HERMES, INC. | $401.609.977 | 5.133.708 | 0,41% | Aktien |
| D. E. Shaw & Co., Inc. | $343.960.178 | 4.396.781 | 0,35% | Aktien |
| M&G PLC | $304.332.132 | 3.901.694 | 0,31% | Aktien |
| Boston Partners | $297.468.910 | 3.802.116 | 0,30% | Aktien |
Aktivisten & 5%+-Eigentümer 2 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Medtronic plc (2), Covidien Group S.a.r.l. (2) | 21. September 2018 | · | Erste Einreichung | · | SEC |
| Medtronic plc, Medtronic, Inc., Medtronic International, Ltd. | 16. Februar 2016 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 46 Insider · 26 Führungskräfte · 19 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Geoffrey Martha | Chairman and CEO | 3. August 2026 A | 327.866 | 0 | 0 | $0 |
| Thierry Pieton | EVP & Chief Financial Officer | 3. August 2026 A | 49.645 | 0 | 0 | $0 |
| Gary Louis Corona | Interim CFO | 21. Januar 2025 A | 44.255 | 0 | 0 | $0 |
| Karen L Parkhill | EVP & Chief Financial Officer | 2. August 2024 M | 46.730 | 0 | 0 | $0 |
| Harry Skip Kiil | EVP & President Cardiovascular | 16. September 2026 S | 42.186 | 0 | 8 | $-5.607.959 |
| Denise L. Blomquist | Chief Accounting Officer | 15. September 2026 G | 16.398 | 0 | 0 | $0 |
| Michael Marinaro | EVP, Pres MedSurg and Americas | 20. August 2026 F | 116.336 | 0 | 0 | $0 |
| Kweli Thompson | EVP & President, Neuroscience | 3. August 2026 A | 35.390 | 0 | 0 | $0 |
| Matthew R. Walter | SVP, Chief HR Officer | 3. August 2026 A | 39.928 | 0 | 1 | $-257.931 |
| Michelle Quinn | EVP, GC and Secretary | 3. August 2026 A | 26.721 | 0 | 0 | $0 |
| Brett A. Wall | EVP & Pres Neuroscience | 26. Mai 2026 M | 82.183 | 0 | 0 | $0 |
| Gregory L Smith | EVP Global Ops & Supply Chain | 19. November 2025 S | 46.016 | 0 | 7 | $-3.058.452 |
| Sean Salmon | EVP & President Cardiovascular | 16. Dezember 2024 F | 64.722 | 0 | 0 | $0 |
| Ivan K Fong | EVP GENERAL COUNSEL & SECR | 16. Dezember 2024 F | 54.692 | 0 | 0 | $0 |
| Jennifer M Kirk | Chief Accounting Officer | 6. Dezember 2024 F | 28.011 | 0 | 0 | $0 |
| Robert John White | EVP & Pres. Medical Surgical | 8. Dezember 2023 F | 48.410 | 0 | 0 | $0 |
| Rob Ten Hoedt | EVP and Pres. Global Regions | 3. August 2023 M | 52.748 | 0 | 0 | $0 |
| Carol A Surface | EVP, Chief HR Officer | 1. August 2022 A | 26.193 | 0 | 0 | $0 |
| John R Liddicoat | EVP & President of Americas | 29. Juli 2022 D | 37.374 | 0 | 0 | $0 |
| Bradley E Lerman | SVP General Counsel & Corp Sec | 5. November 2021 F | 48.635 | 0 | 0 | $0 |
| Richard Kuntz | SVP & Chief Medical & Science | 5. November 2021 F | 74.945 | 0 | 0 | $0 |
| Michael J Coyle | EVP & Group Pres, Cardiac&Vasc | 3. November 2020 F | 190.390 | 0 | 0 | $0 |
| Omar Ishrak | Executive Chairman | 15. Oktober 2020 G | 8.650 | 0 | 0 | $0 |
| Hooman Hakami | EVP & Group President Diabetes | 10. September 2019 M | 30.761 | 0 | 0 | $0 |
| Bryan C Hanson | EVP, President, MITG | 15. Dezember 2017 S | 88.818 | 0 | 0 | $0 |
| Gary Lee Ellis | EVP & Global Ops and IT | 30. Dezember 2016 G | 180.718 | 0 | 0 | $0 |
| Gregory P Lewis | Direktor | 28. April 2026 F | 5.754 | 0 | 0 | $0 |
| Elizabeth G Nabel | Direktor | 28. April 2026 F | 19.584 | 0 | 0 | $0 |
| Kevin E Lofton | Direktor | 28. April 2026 F | 10.140 | 0 | 0 | $0 |
| Lidia Fonseca | Direktor | 28. April 2026 F | 7.644 | 0 | 0 | $0 |
| Randall J Hogan | Direktor | 28. April 2026 F | 48.998 | 0 | 0 | $0 |
| Craig Arnold | Direktor | 28. April 2026 F | 42.185 | 0 | 0 | $0 |
| Joon Sup Lee | Direktor | 27. April 2026 A | 1.803 | 0 | 0 | $0 |
| John P Groetelaars | Direktor | 27. April 2026 A | 1.444 | 0 | 0 | $0 |
| William R Jellison | Direktor | 27. April 2026 A | 6.444 | 0 | 0 | $0 |
| Andrea Jo Goldsmith | Direktor | 29. April 2025 F | 10.247 | 0 | 0 | $0 |
| Denise M Oleary | Direktor | 1. Mai 2024 F | 77.057 | 0 | 0 | $0 |
| Richard H Anderson | Direktor | 2. Mai 2023 F | 113.023 | 0 | 0 | $0 |
| Michael O Leavitt | Direktor | 3. Mai 2021 A | 21.779 | 0 | 0 | $0 |
| James T Lenehan | Direktor | 3. Mai 2021 A | 57.849 | 0 | 0 | $0 |
| Robert C Pozen | Direktor | 23. August 2018 M | 60.964 | 0 | 0 | $0 |
| Shirley A Jackson | Direktor | 1. Mai 2018 F | 38.525 | 0 | 0 | $0 |
| Preetha Reddy | Direktor | 2. Mai 2016 A | 7.823 | 0 | 0 | $0 |
| Kendall J Powell | · | 28. April 2026 F | 51.380 | 0 | 0 | $0 |
| Scott C Donnelly | · | 28. April 2026 F | 23.679 | 0 | 0 | $0 |
| Christopher J Oconnell | · | 19. Februar 2015 M | 93.274 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 111 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IHI · iShares Trust | 5,01% | 1.737.977 SH | 11. September 2026 | Täglich |
| CAMX · ADVISORS' INNER CIRCLE FUND | 3,61% | 28.750 NS | 31. Juli 2026 | N-PORT |
| ELCV · Strategy Shares | 3,07% | 90.286 NS | 31. Juli 2026 | N-PORT |
| GEND · Spinnaker ETF Series | 2,79% | 1.586 NS | 31. Juli 2026 | N-PORT |
| ESLV · Strategy Shares | 2,55% | 4.262 NS | 31. Juli 2026 | N-PORT |
| SPHD · Invesco Exchange-Traded Fund Trust … | 1,92% | 697.130 SH | 2. Oktober 2026 | Täglich |
| IYH · iShares Trust | 1,89% | 750.817 SH | 11. September 2026 | Täglich |
| HDV · iShares Trust | 1,83% | 3.067.597 SH | 11. September 2026 | Täglich |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,57% | 156.661 SH | 2. Oktober 2026 | Täglich |
| IXJ · iShares Trust | 1,49% | 674.832 SH | 11. September 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 1,48% | 3.859.616 SH | 19. August 2026 | Täglich |
| CURE · Direxion Shares ETF Trust | 1,26% | 25.264 NS | 31. Juli 2026 | N-PORT |
| CVAR · ETF Opportunities Trust | 1,03% | 5.189 NS | 31. Juli 2026 | N-PORT |
| ESUM · Strategy Shares | 0,98% | 20.963 NS | 31. Juli 2026 | N-PORT |
| EQWL · Invesco Exchange-Traded Fund Trust | 0,97% | 306.508 SH | 1. Oktober 2026 | Täglich |
| DGRO · iShares Trust | 0,89% | 4.197.194 SH | 11. September 2026 | Täglich |
| SPLV · Invesco Exchange-Traded Fund Trust … | 0,88% | 697.046 SH | 2. Oktober 2026 | Täglich |
| DIVB · iShares Trust | 0,73% | 161.785 SH | 11. September 2026 | Täglich |
| PICB · Invesco Exchange-Traded Fund Trust … | 0,69% | 2.600.000 | 2. Oktober 2026 | Täglich |
| VFVA · VANGUARD WELLINGTON FUND | 0,53% | 57.783 SH | 19. August 2026 | Täglich |
| CATH · Global X Funds | 0,52% | 79.374 NS | 31. Juli 2026 | N-PORT |
| MGV · VANGUARD WORLD FUND | 0,47% | 806.965 SH | 19. August 2026 | Täglich |
| DFUV · Dimensional ETF Trust | 0,44% | 802.456 NS | 31. Juli 2026 | N-PORT |
| VIG · VANGUARD SPECIALIZED FUNDS | 0,44% | 7.253.284 SH | 19. August 2026 | Täglich |
| DFLV · Dimensional ETF Trust | 0,44% | 347.054 NS | 31. Juli 2026 | N-PORT |
| IWX · iShares Trust | 0,44% | 184.938 SH | 11. September 2026 | Täglich |
| VYM · VANGUARD WHITEHALL FUNDS | 0,42% | 5.120.062 SH | 19. August 2026 | Täglich |
| PFM · Invesco Exchange-Traded Fund Trust | 0,41% | 36.487 SH | 2. Oktober 2026 | Täglich |
| VFMV · VANGUARD WELLINGTON FUND | 0,41% | 21.916 SH | 19. August 2026 | Täglich |
| IVE · iShares Trust | 0,39% | 2.132.370 SH | 11. September 2026 | Täglich |
| ESLG · Strategy Shares | 0,38% | 1.039 NS | 31. Juli 2026 | N-PORT |
| LQAI · Exchange Listed Funds Trust | 0,38% | 99 NS | 31. Juli 2026 | N-PORT |
| VTV · VANGUARD INDEX FUNDS | 0,38% | 12.209.067 SH | 19. August 2026 | Täglich |
| IUSV · iShares Trust | 0,37% | 1.124.340 SH | 11. September 2026 | Täglich |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,37% | 40.639 SH | 2. Oktober 2026 | Täglich |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,35% | 295.656 SH | 19. August 2026 | Täglich |
| ILCV · iShares Trust | 0,34% | 49.972 SH | 11. September 2026 | Täglich |
| CHRI · Global X Funds | 0,33% | 312 NS | 31. Juli 2026 | N-PORT |
| IWD · iShares Trust | 0,32% | 2.850.325 SH | 11. September 2026 | Täglich |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,31% | 430.000 | 2. Oktober 2026 | Täglich |
| DYNF · BlackRock ETF Trust | 0,31% | 1.390.566 SH | 11. September 2026 | Täglich |
| PRF · Invesco Exchange-Traded Fund Trust | 0,29% | 322.466 SH | 2. Oktober 2026 | Täglich |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,28% | 774.434 SH | 19. August 2026 | Täglich |
| EGLE · Global X Funds | 0,25% | 65 NS | 31. Juli 2026 | N-PORT |
| LRGF · iShares Trust | 0,25% | 100.146 SH | 11. September 2026 | Täglich |
| OEF · iShares Trust | 0,25% | 543.832 SH | 11. September 2026 | Täglich |
| ACVF · ETF Opportunities Trust | 0,24% | 4.220 NS | 31. Juli 2026 | N-PORT |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,23% | 8.138.000 | 1. Oktober 2026 | Täglich |
| VFMF · VANGUARD WELLINGTON FUND | 0,22% | 20.156 SH | 19. August 2026 | Täglich |
| TOPC · iShares Trust | 0,22% | 778 SH | 11. September 2026 | Täglich |
| SIZE · iShares Trust | 0,21% | 9.868 SH | 11. September 2026 | Täglich |
| IWL · iShares Trust | 0,21% | 49.941 SH | 11. September 2026 | Täglich |
| XVV · iShares Trust | 0,20% | 14.747 SH | 11. September 2026 | Täglich |
| EUSA · iShares, Inc. | 0,20% | 41.451 SH | 11. September 2026 | Täglich |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,20% | 37.758 SH | 2. Oktober 2026 | Täglich |
| RSP · Invesco Exchange-Traded Fund Trust | 0,19% | 2.123.890 SH | 2. Oktober 2026 | Täglich |
| MGC · VANGUARD WORLD FUND | 0,19% | 256.431 SH | 19. August 2026 | Täglich |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,18% | 203.477 SH | 2. Oktober 2026 | Täglich |
| IVV · iShares Trust | 0,18% | 16.182.808 SH | 11. September 2026 | Täglich |
| ILCB · iShares Trust | 0,18% | 24.968 SH | 11. September 2026 | Täglich |
| PBP · Invesco Exchange-Traded Fund Trust | 0,17% | 7.616 SH | 1. Oktober 2026 | Täglich |
| XTR · Global X Funds | 0,17% | 96 NS | 31. Juli 2026 | N-PORT |
| XRMI · Global X Funds | 0,17% | 995 NS | 31. Juli 2026 | N-PORT |
| XYLD · Global X Funds | 0,17% | 64.534 NS | 31. Juli 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0,17% | 290.026 SH | 19. August 2026 | Täglich |
| VOTE · TCW ETF Trust | 0,17% | 21.699 NS | 31. Juli 2026 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,17% | 221.603 SH | 2. Oktober 2026 | Täglich |
| IYY · iShares Trust | 0,17% | 55.148 SH | 11. September 2026 | Täglich |
| IWB · iShares Trust | 0,17% | 888.122 SH | 11. September 2026 | Täglich |
| XCLR · Global X Funds | 0,17% | 70 NS | 31. Juli 2026 | N-PORT |
| XYLG · Global X Funds | 0,17% | 1.250 NS | 31. Juli 2026 | N-PORT |
| USCL · iShares Trust | 0,16% | 50.811 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,16% | 353.624 SH | 11. September 2026 | Täglich |
| ITOT · iShares Trust | 0,16% | 1.675.297 SH | 11. September 2026 | Täglich |
| VOO · VANGUARD INDEX FUNDS | 0,16% | 33.351.485 SH | 19. August 2026 | Täglich |
| VV · VANGUARD INDEX FUNDS | 0,16% | 1.499.427 SH | 19. August 2026 | Täglich |
| DFUS · Dimensional ETF Trust | 0,16% | 388.672 NS | 31. Juli 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,16% | 4.844 NS | 31. Juli 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,14% | 78.236 SH | 2. Oktober 2026 | Täglich |
| DFSU · Dimensional ETF Trust | 0,14% | 38.336 NS | 31. Juli 2026 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0,14% | 1.008 SH | 1. Oktober 2026 | Täglich |
| DFAU · Dimensional ETF Trust | 0,14% | 205.693 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,14% | 40.764.368 SH | 19. August 2026 | Täglich |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,14% | 212.203 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,14% | 107.997 SH | 19. August 2026 | Täglich |
| USMV · iShares Trust | 0,14% | 354.161 SH | 11. September 2026 | Täglich |
| TOK · iShares Trust | 0,14% | 3.513 SH | 11. September 2026 | Täglich |
| HCMT · Direxion Shares ETF Trust | 0,14% | 8.934 NS | 31. Juli 2026 | N-PORT |
| URTH · iShares, Inc. | 0,13% | 114.782 SH | 11. September 2026 | Täglich |
| SPXL · Direxion Shares ETF Trust | 0,13% | 100.374 NS | 31. Juli 2026 | N-PORT |
| ACWI · iShares Trust | 0,11% | 406.346 SH | 11. September 2026 | Täglich |
| PXF · Invesco Exchange-Traded Fund Trust … | 0,10% | 32.728 SH | 2. Oktober 2026 | Täglich |
| DCOR · Dimensional ETF Trust | 0,10% | 38.357 NS | 31. Juli 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 8.251 SH | 2. Oktober 2026 | Täglich |
| DFAC · Dimensional ETF Trust | 0,09% | 495.866 NS | 31. Juli 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,08% | 1.062.069 SH | 19. August 2026 | Täglich |
| CRBN · iShares Trust | 0,07% | 9.255 SH | 11. September 2026 | Täglich |
| DXUV · Dimensional ETF Trust | 0,04% | 2.811 NS | 31. Juli 2026 | N-PORT |
| GLOF · iShares Trust | 0,02% | 377 SH | 9. September 2026 | Täglich |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 15. Juli 2026 | Täglich |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 15. Juli 2026 | Täglich |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15. Juli 2026 | Täglich |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15. Juli 2026 | Täglich |
| VUSB · VANGUARD BOND INDEX FUNDS | · | · | 15. Juli 2026 | Täglich |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15. Juli 2026 | Täglich |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 15. Juli 2026 | Täglich |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15. Juli 2026 | Täglich |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30. Juli 2026 | Täglich |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30. Juli 2026 | Täglich |
| BNDX · VANGUARD CHARLOTTE FUNDS | · | · | 15. Juli 2026 | Täglich |
| VCEB · VANGUARD WORLD FUND | · | · | 30. Juli 2026 | Täglich |
MDT Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 34 Analysten
KAUF
Median-Ziel
$106.00
+22,7%
10 29,4%
Starker Kauf
13 38,2%
Kauf
11 32,4%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
24 Analysten · 2026-10-03Mittelwert-Ziel $104.83 +21,4%
Jetzt
Aktueller Preis $86.38
Tief$85.00
Mittelwert$104.83
Hoch$121.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Medtronic's High Dividend Yield Gets Little Attention on Wall Street -- Should You Buy the Stock Anyway?
Nasdaq · 6 Tage, 16 Stunden vor
US jury says Medtronic owes $88 million in first case to go to trial over Covidien's hernia mesh
Yahoo Finance · 1 Monat, 4 Wochen vor
Got $2,500? 1 Unstoppable Medical Juggernaut to Buy Hand Over Fist and Hold for the Next 20 Years
Yahoo Finance · 3 Monate, 2 Wochen vor
How To Earn $500 A Month From Medtronic Stock After Q4 Earnings
Yahoo Finance · 3 Monate, 4 Wochen vor
Täglicher Dividendenbericht: MDT, ACM, UNH, RICK, VRT
Nasdaq · 4 Monate vor
Warum Medtronic-Aktie heute sprang
Nasdaq · 4 Monate vor
3 Gesundheitsversicherungsaktien, die jeder Rentner berücksichtigen sollte
Nasdaq · 4 Monate, 3 Wochen vor
Besser als Intuitive Surgical? 1 Under-the-Radar Healthcare Stock zum Kaufen und für immer Halten
Nasdaq · 4 Monate, 3 Wochen vor
Medtronic plc (MDT) erhält die CE Mark für das Stealth AXiS™ chirurgische System
Yahoo Finance · 5 Monate vor
Medtronic sagt, Cyberangriff auf IT-Netzwerk habe den Betrieb nicht gestört
Yahoo Finance · 5 Monate vor
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Sep 3, 2026